A Phase 1 Dose Escalation Study of ARQ 751 in Adult Subjects With Advanced Solid Tumors With AKT1, 2, 3 Genetic Alterations, Activating PI3K Mutations, PTEN-null, or Other Known Actionable PTEN Mutations
Phase of Trial: Phase I
Latest Information Update: 14 Oct 2017
At a glance
- Drugs ARQ 751 (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors ArQule
- 21 Jun 2016 Status changed from not yet recruiting to recruiting.
- 03 May 2016 Status changed from planning to not yet recruiting.
- 01 Feb 2016 New trial record